FGF2 and gastric cancer: Using network pharmacology to identify relevant targets and pathways, this study demonstrated that DT significantly reduces the proliferation and migration of gastric cancer cells and endothelial cells, decreases levels of VEGF and bFGF, and suppresses tumor growth and angiogenesis in vivo, likely via the PI3K/Akt/mTOR pathway (118).